Accordion title open
Show Description
Accordion title close
Close Description

SURPASS-2 Bar chart of patients with at least 10% weight reduction

Percentage of patients with weight reduction ≥10%1,3*
Mounjaro vs Ozempic 1 mg
Study length: 40 weeks

Bar graph showing the percentage of patients with a weight reduction of ≥10% at 40 weeks in adults with type 2 diabetes in the SURPASS-2 study. The graph shows Mounjaro vs Ozempic 1 mg as add-on to metformin. From a mean baseline weight of 203.9 lb (Mounjaro 5 mg, n=470), 209.0 lb (Mounjaro 10 mg, n=469), 206.8 lb (Mounjaro 15 mg, n=469), and 206.6 lb (Ozempic 1 mg, n=468), the percentage of patients with a weight reduction of ≥10% at 40 weeks was 34%, 47%, 57%, and 24%, respectively.